"LEQEMBI Intravenous Infusion" (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20 Eisai Dec 14, 2023 15:39 HKT/SGT Read More
TANAKA Contributes to Global Vascular, a Medical Venture Company Developing a Stent Delivery System for Lower Limb Atherosclerosis TANAKA PRECIOUS METAL GROUP Co., Ltd. Dec 13, 2023 03:00 HKT/SGT Read More
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma Eisai Dec 11, 2023 09:28 HKT/SGT Read More
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand Eisai Nov 30, 2023 15:25 HKT/SGT Read More
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting Eisai Nov 22, 2023 08:28 HKT/SGT Read More
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023 Eisai Nov 20, 2023 16:05 HKT/SGT Read More
Namwiwat Medical Corporation Plc (NAM) enjoys first day on SET Namwiwat Medical Corporation PCL Oct 31, 2023 20:00 HKT/SGT Read More
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023 Eisai Oct 25, 2023 19:43 HKT/SGT Read More
アバンセ・クリニカル、招待を受け、韓国バイオ企業45社に韓国・オーストラリアから米国へのGlobalReady医薬品開発経路を説明 Avance Clinical Oct 19, 2023 12:00 JST Read More
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference Eisai Oct 16, 2023 13:07 HKT/SGT Read More
エーザイ、第16回アルツハイマー病臨床試験会議（CTAD）において「レケンビ」の臨床第III相Clarity AD試験の新規データを含むアルツハイマー病領域の最新データを発表 Eisai Oct 16, 2023 11:00 JST Read More
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023 Eisai Oct 11, 2023 12:07 HKT/SGT Read More
Fujitsu and RIKEN develop AI drug discovery technology utilizing generative AI to predict structural changes in proteins Fujitsu Ltd Oct 10, 2023 15:29 HKT/SGT Read More
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc. Eisai Oct 04, 2023 18:08 HKT/SGT Read More
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance" Eisai Sep 28, 2023 13:49 HKT/SGT Read More
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan Eisai Sep 25, 2023 14:17 HKT/SGT Read More
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem Eisai Sep 12, 2023 18:05 HKT/SGT Read More
CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination with Niraparib in the Treatment of Recurrent Ovarian Cancer CanariaBio Inc Aug 08, 2023 15:00 HKT/SGT Read More
